Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (NCT03430037) | Clinical Trial Compass
By InvitationPhase 2
Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women
United States40 participantsStarted 2018-02-06
Plain-language summary
This is a pilot study to evaluate whether targeting inflammation will help reduce markers of insulin resistance inflammation, bone resorption and physical dysfunction in elderly women with gait disturbance. Positive results of this study would lead to the development of a larger clinical trial examining the effects of this intervention on age-related dysfunction.
Who can participate
Age range70 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria
* Healthy postmenopausal women
* Age ≥ 70 years
Exclusion Criteria
* Abnormality in any of the screening laboratory studies (see below)
* Presence of significant liver or renal disease
* Malignancy (including myeloma)
* Malabsorption
* Hypoparathyroidism
* Hyperparathyroidism
* Acromegaly
* Cushing's syndrome
* Hypopituitarism
* Gastric bypass/reduction
* Malabsorption issues
* Crohn's
* Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase or ESR)
* If diabetic AND on sulfonylureas (like glipizide, glimepiride, glyburide), SGLT2 inhibitors (like dapagliflozin and empagliflozin), or insulin
* Undergoing treatment with any medications that affect bone turnover, including the following:
* adrenocorticosteroids (\> 3 months at any time or \> 10 days within the previous yr), anticonvulsant therapy (within the previous year),
* pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal),
* calcium supplementation of \> 1200 mg/d (within the preceding 3 months),
* bisphosphonates (within the past 3 yrs),
* denosumab,
* estrogen (E) therapy or treatment with a selective E receptor modulator, or teriparatide (within the past yr).
* Subjects with a fracture within the past year
* Subjects taking potentially senolytic agents within the last year: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax
* Subjects currently taking drugs that induce cellular senescen…